MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Home・Akcijų sąrašas・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Uždarymo kaina

12.74 -4.85

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.32

Max

13.52

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-23M -14M
Pardavimai	-22M 72M
Pelno marža	-18.944
Darbuotojai	624
EBITDA	-23M -6.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+40.57% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-639M 2.2B
Ankstesnė atidarymo kaina	17.59
Ankstesnė uždarymo kaina	12.74

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

8.81 / 10.18 Palaikymas ir pasipriešinimas

Adaptive Biotechnologies Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026-04-09 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026-04-09 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-09 23:07; UTC

Rinkos pokalbiai

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026-04-09 22:54; UTC

Rinkos pokalbiai

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026-04-09 20:57; UTC

Svarbiausios naujienos

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026-04-09 20:55; UTC

Uždarbis

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026-04-09 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-09 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026-04-09 20:25; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026-04-09 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-09 19:30; UTC

Svarbiausios naujienos

How Digital Currencies Have Helped Iran -- WSJ

Akcijų palyginimas

Kainos pokytis

Adaptive Biotechnologies Corp Prognozė

Kainos tikslas

By TipRanks

40.57% į viršų

12 mėnesių prognozė

Vidutinis 20.86 USD 40.57%

Aukščiausias 22 USD

Žemiausias 20 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Adaptive Biotechnologies Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Adaptive Biotechnologies Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.81 / 10.18Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.